Transitioning of <i>Helicobacter pylori</i> Therapy from Trial and Error to Antimicrobial Stewardship
<i>Helicobacter pylori</i> is the only major infection for which antimicrobial therapy is not designed using the principles of antimicrobial stewardship. Traditionally, antimicrobial therapy is a susceptibility-based therapy, achieves high cure rates, and includes surveillance programs t...
Saved in:
Main Author: | David Y. Graham (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Crises in Antimicrobial Stewardship: Misuse of Clarithromycin for <i>Helicobacter pylori</i> Therapy
by: David Y. Graham
Published: (2024) -
Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of <i>Helicobacter pylori</i>: Randomized ERADICATE Hp Trial
by: Ira N. Kalfus, et al.
Published: (2020) -
Antibiotic Resistance and Therapy for <i>Helicobacter pylori</i> Infection
by: Stella I. Smith, et al.
Published: (2023) -
Antimicrobial Efficacy of Five Probiotic Strains Against <i>Helicobacter pylori</i>
by: Ilaria Maria Saracino, et al.
Published: (2020) -
Whole Genome Sequencing for Studying <i>Helicobacter pylori</i> Antimicrobial Resistance
by: Belén Fernández-Caso, et al.
Published: (2023)